Fresenius Medical Care AG Q3 FY2026 earnings call

• Leadership Transition: Sherwin Kurangi assumed the role of CEO three weeks prior, emphasizing a focus on expanding continuity of care to drive long-term profitable growth while balancing short-term wins with multi-year strategic planning.
• Product Innovation & Rollout: The company successfully launched two new platforms in the US kidney care market: Multifiltrate Pro for critical care and HVHDF. The 5008X machine rollout is ahead of schedule, with 348 clinics converted (14% of total) and ~9,000 machines installed (16% of install base) by end of September, targeting 20% conversion by year-end.
• Operational Quality & Safety: Management acknowledged recent findings requiring corrective actions, prioritizing accelerated resolution and systemic process improvements to ensure product quality and safety. Clinical quality initiatives helped sustain pre-COVID mortality rates and stabilize patient inflow.
• Transformation Progress: The FME25 Plus transformation program delivered €74 million in sustainable savings during the quarter, keeping the company on track to achieve €250 million in full-year savings through clinic consolidation, manufacturing footprint optimization, and organizational efficiencies.
• Shareholder Returns: Execution of the second €1 billion share buyback program continues, with 3.4% of share capital purchased as of September 30.

• Care Delivery: Revenue increased by 1% at constant currency (2% organic). Operating income rose 2% at constant currency, with margins expanding to 14.7%. Underlying operating income (excluding DARPA effects) surged 21% year-over-year.
• Value-Based Care: Revenue decreased by 9% both organically and at constant currency due to a change in risk contracting structure for a major contract. Operating income excluding special items improved significantly from a €21 million loss to a positive €1 million.
• Care Enablement: Revenue grew solidly by 5% organically and at constant currency, driven by the US rollout of the 5008X care system and favorable global pricing. Earnings increased by 4%, supported by sales momentum and FME25+ savings.

• Inflation Costs: Management raised its inflation cost estimate for the full year, now expecting to exceed the previous top-end assumption of €300 million due to higher oil/gas prices and logistics costs from Middle East tensions affecting both Care Enablement and Care Delivery.
• DARPA Headwinds: Anticipated reimbursement headwinds from DARPA are expected to increase in the fourth quarter as the period for phosphate binders concludes.
• Treatment Growth: US market treatment growth decline for the full year remains revised to approximately 0.9%, though patient inflow showed stabilization in Q3.
• Value-Based Care Revenue: Full-year revenue decline for Value-Based Care is maintained around €150 million.

• Regulatory & Reimbursement Changes: Continued headwinds from DARPA reimbursement structures and potential impacts from the HHS Kidney Care National Plan priorities.
• Legal & Referral Issues: Carry-forward impact of legal patient referrals caused a 1.1% decline in US market treatment growth in Q3.
• Geopolitical & Supply Chain: Increased logistics costs and inflationary pressures stemming from geographical tensions in the Middle East.
• Product Quality & Compliance: Recent operational findings require immediate corrective actions; failure to address these could impact patient safety and regulatory standing.

Q: How does the new CEO view the alignment between the HHS Kidney Care National Plan and Fresenius' strategy? / A: Sherwin Kurangi stated that the plan's priorities align closely with the company’s thinking, particularly regarding innovation. He highlighted that bringing two new platforms (Multifiltrate Pro and HVHDF) to market quickly demonstrates this alignment. The focus remains on providing access to therapies with strong demonstrated outcomes, which supports the broader goal of improving continuity of care.

Q: What drove the significant improvement in Value-Based Care profitability despite the revenue decline? / A: CFO Martin Fischer explained that operating income turned positive due to business growth contributions and higher savings rates. Additionally, a favorable prior year comparison helped, as delays in CMS reporting data had deferred revenue recognition to Q4 2025 previously. Integration synergies from the FME25+ program also contributed to the earnings improvement.

Q: Can you elaborate on the factors causing the upward revision in full-year inflation costs? / A: Management cited higher than expected inflationary pressures, specifically noting increases in raw material costs due to oil and gas prices. Furthermore, logistical disruptions caused by geographical tensions in the Middle East have increased transportation costs. These factors affect both Care Enablement and Care Delivery segments, pushing total inflation costs above the initial €300 million ceiling.

Q: What is the current status of the 5008X rollout and early feedback from providers? / A: The rollout is progressing ahead of expectations, with 348 clinics converted by end-September. Feedback has been overwhelmingly positive, with providers highlighting improvements in patient and staff experience. Crucially, the system helps address workforce attraction and retention challenges, which is a key priority for healthcare providers.